Global CNS Therapeutics Market to Reach US$144.2 Billion by the Year 2027

Abstract: Global CNS Therapeutics Market to Reach US$144. 2 Billion by the Year 2027. Amid the COVID-19 crisis, the global market for CNS Therapeutics estimated at US$103.

New York, July 12, 2021 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Global CNS Therapeutics Industry" - https://www.reportlinker.com/p06050565/?utm_source=GNW
4 Billion in the year 2020, is projected to reach a revised size of US$144.2 Billion by 2027, growing at a CAGR of 4.9% over the analysis period 2020-2027.Pain Management, one of the segments analyzed in the report, is projected to grow at a 5.5% CAGR to reach US$41.4 Billion by the end of the analysis period.After an early analysis of the business implications of the pandemic and its induced economic crisis, growth in the Anti-Psychotics segment is readjusted to a revised 3.9% CAGR for the next 7-year period. This segment currently accounts for a 14.8% share of the global CNS Therapeutics market.

The U.S. Accounts for Over 27% of Global Market Size in 2020, While China is Forecast to Grow at a 8% CAGR for the Period of 2020-2027

The CNS Therapeutics market in the U.S. is estimated at US$27.9 Billion in the year 2020. The country currently accounts for a 26.98% share in the global market. China, the world second largest economy, is forecast to reach an estimated market size of US$30.6 Billion in the year 2027 trailing a CAGR of 8% through 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 2.7% and 3.9% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 3.5% CAGR while Rest of European market (as defined in the study) will reach US$30.6 Billion by the year 2027.

Anti-Depressants Segment Corners a 11.8% Share in 2020

In the global Anti-Depressants segment, USA, Canada, Japan, China and Europe will drive the 3.4% CAGR estimated for this segment. These regional markets accounting for a combined market size of US$9.2 Billion in the year 2020 will reach a projected size of US$11.6 Billion by the close of the analysis period. China will remain among the fastest growing in this cluster of regional markets. Led by countries such as Australia, India, and South Korea, the market in Asia-Pacific is forecast to reach US$19.4 Billion by the year 2027, while Latin America will expand at a 3.9% CAGR through the analysis period.

Select Competitors (Total 181 Featured)

• AbbVie Inc.

• Alkermes Plc.

• Allergan Plc.

• AstraZeneca Plc.

• Bristol-Myers Squibb

• Eisai Co., Ltd.

• Eli Lilly and Co.

• Endo Pharmaceuticals Inc.

• F. Hoffmann-La Roche Ltd.

• GlaxoSmithKline Plc

• H. Lundbeck A/S

• Janssen Pharmaceuticals Inc.

• Merck & Co., Inc.

• Neurocrine Biosciences, Inc.

• Novartis AG

• Otsuka Pharmaceutical Co. Ltd.

• Pfizer Inc.

• Purdue Pharma L.P.

• Sanofi

• Shire Plc

• Sumitomo Dainippon Pharma Co., Ltd.

• Takeda Pharmaceutical Co., Ltd.

• Teva Pharmaceutical Industries Ltd.

• UCB Group

Read the full report: https://www.reportlinker.com/p06050565/?utm_source=GNW

I. METHODOLOGY

II. EXECUTIVE SUMMARY

1. MARKET OVERVIEW
Influencer Market Insights
World Market Trajectories
Impact of Covid-19 and a Looming Global Recession
Central Nervous System (CNS) Therapeutics: A Prelude
CNS Therapeutics Exhibit Robust Opportunities amidst Rising
Incidence of CNS Disorders
List of FDA Approved CNS Drugs: 2019
List of FDA Approved CNS Drugs: 2018
Patent Expiries of Major Drugs Exert Downward Pressure on the
Global CNS Market
Patent Expiries of Leading CNS Drugs: 2008-2022
Developed Markets to Maintain their Dominance
Developing Market to Drive the Market Momentum
MARKET ANALYSIS BY THERAPEUTIC CATEGORY
Anti-Epilepsy Market
Global Market Overview
Regional Landscape
Developed Countries Account for a Major Share of Epilepsy
Treatment
Developing Countries Struggle with Low Treatment Rates
New Approvals (2019 and 2018)
Disease Overview
EXHIBIT 1: Epilepsy Incidence by Type (2019): Percentage Share
Breakdown for Idiopathic and Symptomatic Epilepsy
EXHIBIT 2: Symptomatic Epilepsy Incidence by Type (2019):
Percentage Share Breakdown of Congenital, Degenerative,
Infective, Neoplastic, Trauma, and Vascular Epilepsy
High Unmet Needs Offer Scope for Market Growth
Treatment
Anti-Epileptic Drugs (AEDs) by Generic Name and Brand Names
Leading Anti-Epileptic Drugs
Leading Anti-Epileptic Drugs and Their Mechanism of Action
Patent Expiries of Major Anti-Epilepsy Drugs
FDA’s New Policy for AED Drugs to Bolster Market Growth
AAN Updated Guidelines on New AEDs Use for Treating New Onset
Epilepsy (2019)
Select Currently Available Epilepsy Drugs
Select Anti-Epilepsy Drugs (AEDs) in Phase III Trials
Innovative Drugs Needed for Better Treatment Compliance
Abounding Potential for NCEs
A New Research Demonstrates Effectiveness of Gluconate in
Treating Neonatal Seizures
FDA Approves Epidiolex (Cannabidiol) - First Drug for Treating
Dravet Syndrome and Lennox-Gastaut Syndrome
Refractory Childhood Epilepsy & Pregnancy Epilepsy - Major
Concerns
Recent Approvals for Childhood Epilepsy: 2016-2019
Review of Anti-Epilepsy Drugs
Vimpat®
Keppra®
Lamictal
Tegretol®
Sabril®
Perampanel
Zonegran®
Topamax®
Trileptal®
Neurontin®
Lyrica®
Depakine®
CNS Pain Management
Market Overview
Treatment
Drugs Indicated for Pain Management
Select Phase III Ongoing Studies for Cancer Pain
Regional Overview
Players
Combination Therapies Gain Prominence
Key Trends in Chronic Pain Management
Neuropathic Pain Management: Market with High Potential
Select Phase III Ongoing Studies for Neuropathic Pain
Lyrica’s Generics Gain FDA Approval
Migraine Market: A Core Vertical in CNS Pain Management
Migraine Care: Select Patent Expiries (2013-2015)
Migraine Completed Phase III Studies: As of October 2019
Migraine Ongoing Phase III Studies: As of October 2019
Select Pain Management Drugs
Flupirtine
Lyrica
Oxycodone
Nucynta ER
Metabotropic Glutamate Receptors (mGluRs)
New Pain Management Drugs
Novartis Presents New Data for Aimovig
Reyvow, Eli Lilly’s Novel Migraine Drug with the Potential to
Lead the Global Migraine Medications Market
Three New Migraine Drugs Obtain FDA Approval
Eli Lilly’s Emgality Receives FDA Approval
Anti-Alzheimer’s
Market Overview
EXHIBIT 3: Global Alzheimer’s Prevalence by Age Group
Alzheimer’s Phase III Completed Studies
Alzheimer’s Phase III Ongoing Studies
Treatment for Alzheimer’s
Select Leading Drugs for Alzheimer’s Disease by Drug Category
Patent Expiries of Leading Alzheimer’s Drugs
Aducanumab Marches towards FDA Approval, Following being
Abondoned by Biogen a few Months Ago
The Clinical Trials for Aducanumab
Aducanumab: A Promising Drug Which would Revolutionalize the
Alzheimer’s Market
Alzheimer’s Drugs: A Market Plagued with Failures
Promising Compounds with Silver Lining
PRI-002 Gains Success in First Stage of Human Testing for
Alzheimer’s Disease
Updated FDA Standards Make Way for Increased Alzheimer?s Drug
Testing
Rising Discontinuation of BACE Programs for Alzheimer’s to
Dampen Market Growth
Rising Discontinuation of BACE Programs for Alzheimer’s to
Dampen Market Growth
Elenbecestat?s Phase 3 Trials Halted
Novel Drug Delivery Method to the Brain Discovered
Alzheimer’s Association Provides Grant to Longeveron
A Review of Select Anti-Alzheimer’s Drugs
Aricept
Exelon
Reminyl
Ebixa
Namenda
A Review of the Alzheimer’s disease
Alzheimer?s Effect on Brain
Causes for Alzheimer’s
Who Are at Risk?
Prevalence of Alzheimer?s Disease
Diagnosis of Alzheimer?s
Anti-Parkinson’s
Market Overview
EXHIBIT 4: Select Top Selling Drugs for Parkinson’s Disease
Nourianz, An Add-on Medication for Treating Episodes of
Parkinson?s Disease Secures FDA Approval
Recent Approvals
Novel Drug and a New Delivery Method for Restoring Brain Cells
in People Suffering from PD
Xadago - Add-On Therapy for Parkinson?s Disease
NUPLAZID® - The First and the Only Approved Drug for Psychosis
related to Parkinson?s disease
Parkinson?s Phase III Completed Studies: As of October 2019
Parkinson’s Ongoing Phase III Studies: As of October 2019
Select Anti-Parkinson?s Drugs
Levodopa
Dopamine Agonists
Mirapex
FDA Announces Imminent Discontinuation of Certain Formulations
of GSK?s Requip for PD and RSL Treatment
A Review of the Parkinson?s Disease
Prevalence
Symptoms
Causes
Diagnosis
Anti-Depressants
Market Overview
EXHIBIT 5: Anti-Depressant Market: Percentage Share Breakdown
by Depressive Disorder Type
Anti-Depressant Treatment
EXHIBIT 6: Select Top Selling Anti-Depressants in 2018
Select Antidepressants Drugs
Zoloft (Sertraline)
Cymbalta®
Prozac (Fluoxetine)
Effexor (Venlafaxine)
Paxil
Wellbutrin (Bupropion)
Recent Approvals of Anti-Depressants
Esketamine, the Fast Acting Drug for Depression from Janssen
Receives FDA Approval
Pipeline Drugs in Phase III for Depressive Disorder: As of
October 2019
A Review of Depression
Prevalence of Depression
Causes of Depression
Types of Depressive Disorders
Available Treatment
Tricyclic Antidepressants
Monoamine Oxidase Inhibitors
Lithium Salts
Working of Antidepressants
Ranking of Antidepressants in Terms of Efficacy
Types of Antidepressants
NMDA Receptor Antagonists
NMDA Receptor (NMDAR)
NMDA Receptor Agonists
Acetylcholinesterase Inhibitors
Selective Serotonin Reuptake Inhibitors (SSRIs)
Workings of SSRIs
Safety Levels of SSRI Drugs
Adverse Effects of SSRI
Serotonin Noradrenaline Reuptake Inhibitors (SNRIs)
Anti-Psychotics
Market Overview
Leading Atypical Antipsychotics for the Treatment of Schizophrenia
Pipeline Drugs in Phase III for Schizophrenia: As of October 2019
Pipeline Drugs in Phase III for Bipolar Disorder: As of October
2019
Select Anti-Psychotic Drugs
Zyprexa
Seroquel
Abilify
Clozaril
Risperdal
Risperdal® Consta®
Geodon
Invega Sustenna
Saphris
Latuda
A Review of Anti-Psychotics
Indications of Antipsychotics
An Effective Adjunctive Therapy
Off-label Uses
Efficacy - Marred by Lack of Evidence Base
Types of Antipsychotics
Difference between Typical and Atypical
Atypical Antipsychotics Up Against Typicals
Side Effects of Antipsychotics
Symptoms of Antipsychotics Withdrawal
Bipolar Disorder
Symptoms of Bipolar Disorder
Mood Episode - A Major Symptom
Manic Episode Vs Depressive Episode
Causes of Bipolar Disorder
Types of Bipolar Disorder
Co-morbidities of Bipolar Disorder
Schizophrenia
Prevalence by Gender
Symptoms of Schizophrenia
Causes of Schizophrenia
Other CNS Disorders (Multiple Sclerosis, Attention Deficit
Hyperactivity Disorder (ADHD), and Insomnia)
Multiple Sclerosis (MS)
List of Approved Drugs for MS
Patent Expiration Date/Year of the Major MS Drugs
EXHIBIT 7: Leading Multiple Sclerosis Drugs (2018): Sales in
USD Million
New Approvals
Novartis Receives FDA Approval for Mayzent for Use in Multiple
Sclerosis
Mavenclad Gains FDA Approval
Celgene Files NDA for Ozanimod
Ocrevus - The First Approved Drug for Primary Progressive
Multiple Sclerosis (PPMS)
Multiple Sclerosis: Pipeline Analysis
Pipeline Drugs in Phase III for Multiple Sclerosis: As of
October 2019
A Review of Multiple Sclerosis (MS)
Types of Multiple Sclerosis
EXHIBIT 8: Clinical Subtypes of Multiple Sclerosis (MS)
Prevalence of MS
Causes of MS
Myths Surrounding Multiple Sclerosis
Symptoms of MS
Diagnosis of MS
Attention Deficit Hyperactivity Disorder (ADHD)
Market Overview
Approved Drugs for ADHD: 2017
Sales of Vyvanse in 2018
Pipeline Drugs in Phase III for ADHD: As of October 2019
Select ADHD Drugs
Vyvanse
Concerta
Adderall
A Review of Attention Deficit Hyperactivity Disorder (ADHD)
Consequences of ADHD
What Leads to ADHD?
Insomnia
Overview
List of Approved Drugs for Insomnia
Pipeline Drugs for Insomnia: As of October 2019
Zolpidem
Eszopiclone
A Review of Insomnia
Prevalence of Insomnia
Therapies for Insomnia

2. FOCUS ON SELECT PLAYERS
AbbVie Inc. (USA)
Alkermes Plc. (Ireland)
Allergan Plc. (Ireland)
AstraZeneca Plc. (UK)
BIAL Group (Portugal)
Bristol-Myers Squibb (USA)
Eisai Co., Ltd. (Japan)
Endo Pharmaceuticals Inc. (USA)
Eli Lilly and Co. (USA)
F. Hoffmann-La Roche Ltd. (Switzerland)
Fabre-Kramer Pharmaceuticals, Inc. (USA)
GlaxoSmithKline (UK)
H. Lundbeck A/S (Denmark)
Johnson & Johnson (USA)
Janssen Pharmaceuticals, Inc. (USA)
Merck & Co., Inc. (USA)
Neurocrine Biosciences, Inc. (USA)
Novartis AG (Switzerland)
Otsuka Pharmaceutical Co., Ltd. (Japan)
Pfizer, Inc. (USA)
Purdue Pharma L.P. (USA)
Sanofi (France)
Sumitomo Dainippon Pharma Co., Ltd. (Japan)
Sunovion Pharmaceuticals, Inc. (USA)
Takeda Pharmaceutical Co., Ltd. (Japan)
Teva Pharmaceutical Industries Ltd. (Israel)
UCB S.A., (Belgium)

3. MARKET TRENDS & DRIVERS
Burgeoning Global Aging Populace, Longer Life Expectancy to
Drive CNS Demand
EXHIBIT 9: Global Population Statistics for the 65+ Age Group
in Million by Geographic Region for the Years 2019, 2025, 2035
and 2050
Increased Spending on Prescription Drugs Bodes Well for the CNS
Therapeutics Market
Rising Healthcare Expenditure to Boost CNS Therapeutics Market
EXHIBIT 10: World Healthcare Expenditure (In US$ Trillion) for
the Years 2017, 2019, 2021 & 2023
EXHIBIT 11: Per Capita Healthcare Expenditure (in $) by Select
Countries for 2018
Growing Middle Class Population in Emerging Regions to Spur the
Market
EXHIBIT 12: Global Middle Class Population (In Million) by
Region for the Years 2020, 2025 and 2030
EXHIBIT 13: Global Middle Class Spending (US$ Trillion) by
Region for the Years 2020, 2025, 2030
Growing Penetration of Generic Drugs Emerges as a Key Trait
EXHIBIT 14: Global Spending on Generic Drugs Vis-à-vis Branded
Drugs (2019): Percentage Share Breakdown of Dollar Spending by
Drug Category
Developments in CNS Drug Delivery Technologies Bode Well for
the CNS Drugs Market
Understanding of BBB Cell Biology & Its Positive Impact on
Epilepsy Drugs: A Case-in-Point
Pharma Companies: Seeking New Tools to Offset Pressure on Drug
Pipelines
Awareness Campaigns Launched by Pharma Companies to Benefit the
Market
Music and Memory Programs Positively Impact Alzheimer?s Disease
(AD) and Related Dementia (ADRD) Patients
New Method to Isolate Active Compounds Related to Alzheimers
from Plant Medicines

4. GLOBAL MARKET PERSPECTIVE
Table 1: World Current & Future Analysis for CNS Therapeutics
by Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2020 through 2027 and % CAGR

Table 2: World Historic Review for CNS Therapeutics by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019 and % CAGR

Table 3: World 15-Year Perspective for CNS Therapeutics by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa Markets for Years 2012, 2020 & 2027

Table 4: World Current & Future Analysis for Pain Management by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2020 through 2027 and % CAGR

Table 5: World Historic Review for Pain Management by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019 and % CAGR

Table 6: World 15-Year Perspective for Pain Management by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa for Years 2012, 2020 & 2027

Table 7: World Current & Future Analysis for Anti-Psychotics by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2020 through 2027 and % CAGR

Table 8: World Historic Review for Anti-Psychotics by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019 and % CAGR

Table 9: World 15-Year Perspective for Anti-Psychotics by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa for Years 2012, 2020 & 2027

Table 10: World Current & Future Analysis for Anti-Depressants
by Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2020 through 2027 and % CAGR

Table 11: World Historic Review for Anti-Depressants by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019 and % CAGR

Table 12: World 15-Year Perspective for Anti-Depressants by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa for Years 2012, 2020 & 2027

Table 13: World Current & Future Analysis for Anti-Epilepsy by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2020 through 2027 and % CAGR

Table 14: World Historic Review for Anti-Epilepsy by Geographic
Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin
America, Middle East and Africa Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2012 through 2019 and
% CAGR

Table 15: World 15-Year Perspective for Anti-Epilepsy by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa for Years 2012, 2020 & 2027

Table 16: World Current & Future Analysis for Anti-Alzheimer`s
by Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2020 through 2027 and % CAGR

Table 17: World Historic Review for Anti-Alzheimer`s by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019 and % CAGR

Table 18: World 15-Year Perspective for Anti-Alzheimer`s by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa for Years 2012, 2020 & 2027

Table 19: World Current & Future Analysis for Anti-Parkinson`s
by Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2020 through 2027 and % CAGR

Table 20: World Historic Review for Anti-Parkinson`s by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019 and % CAGR

Table 21: World 15-Year Perspective for Anti-Parkinson`s by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa for Years 2012, 2020 & 2027

Table 22: World Current & Future Analysis for Other Segments by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2020 through 2027 and % CAGR

Table 23: World Historic Review for Other Segments by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019 and % CAGR

Table 24: World 15-Year Perspective for Other Segments by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa for Years 2012, 2020 & 2027

III. MARKET ANALYSIS

UNITED STATES
Aging Population: A Strong Demographic Driver
EXHIBIT 15: North American Elderly Population by Age Group:
(1975-2050)
The Largest CNS Therapeutics Market Globally
Patent Expiries of Leading CNS Drugs in the US
Focus on Select Markets
Alzheimer?s Market
Anti-depressant Drugs
Usage of Antidepressants Surges in the US
Anti-Epilepsy Market
Epilepsy - A Major Concern for the Healthcare Industry
A Glance at Epilepsy Statistics
Anti-Epilepsy Drugs
The US Epilepsy Market: Patent Expiry of Select Major Drugs
Epilepsy in Children
Growing Competition from Generics
Pain Management Market
Consumers in the US Seek Different Options for Chronic Pain
Management
Neuropathic Pain Market
Anti-Psychotic Drugs Market
Mental Illnesses - Epidemiology
Facts & Figures
EXHIBIT 16: Lifetime Prevalence (%) of Bipolar Disorder in the
US Population by Age Group
Popular Antipsychotic Drugs in the US
Table 40: The US Anti-Psychotic Drugs Market by Indication
(2019E): Percentage Share Breakdown of Value Sales
Surging Off-label Prescriptions
Generics Occupy Front Seat
Rising Antipsychotic Use among Children - A Cause of Concern
ADHD Market
Select Available ADHD Drugs in the US
EXHIBIT 17: The US ADHD Drugs Market by Drug Category (2019E):
Market Share Breakdown of Total Prescription Sales for
Stimulants (Amphetamines and Methylphenidates) and Non-
Stimulants
EXHIBIT 18: The US ADHD Drugs Market by Type (2019E): Market
Share Breakdown of Total Prescription Sales for Branded &
Generic Drugs Groups
Adult ADHD Drugs Continue to Widen their Share
EXHIBIT 19: The US ADHD Drugs Market by Drug Category (2019E):
Percentage Share Breakdown of Total Prescriptions for Adult &
Pediatric Patient Groups
Market Analytics
Table 25: USA Current & Future Analysis for CNS Therapeutics by
Segment - Pain Management, Anti-Psychotics, Anti-Depressants,
Anti-Epilepsy, Anti-Alzheimer`s, Anti-Parkinson`s and Other
Segments - Independent Analysis of Annual Sales in US$ Million
for the Years 2020 through 2027 and % CAGR

Table 26: USA Historic Review for CNS Therapeutics by Segment -
Pain Management, Anti-Psychotics, Anti-Depressants,
Anti-Epilepsy, Anti-Alzheimer`s, Anti-Parkinson`s and Other
Segments Markets - Independent Analysis of Annual Sales in US$
Million for Years 2012 through 2019 and % CAGR

Table 27: USA 15-Year Perspective for CNS Therapeutics by
Segment - Percentage Breakdown of Value Sales for Pain
Management, Anti-Psychotics, Anti-Depressants, Anti-Epilepsy,
Anti-Alzheimer`s, Anti-Parkinson`s and Other Segments for the
Years 2012, 2020 & 2027

CANADA
CNS Diseases: Facts & Figures
Table 28: Canada Current & Future Analysis for CNS Therapeutics
by Segment - Pain Management, Anti-Psychotics,
Anti-Depressants, Anti-Epilepsy, Anti-Alzheimer`s,
Anti-Parkinson`s and Other Segments - Independent Analysis of
Annual Sales in US$ Million for the Years 2020 through 2027 and
% CAGR

Table 29: Canada Historic Review for CNS Therapeutics by
Segment - Pain Management, Anti-Psychotics, Anti-Depressants,
Anti-Epilepsy, Anti-Alzheimer`s, Anti-Parkinson`s and Other
Segments Markets - Independent Analysis of Annual Sales in US$
Million for Years 2012 through 2019 and % CAGR

Table 30: Canada 15-Year Perspective for CNS Therapeutics by
Segment - Percentage Breakdown of Value Sales for Pain
Management, Anti-Psychotics, Anti-Depressants, Anti-Epilepsy,
Anti-Alzheimer`s, Anti-Parkinson`s and Other Segments for the
Years 2012, 2020 & 2027

JAPAN
Table 31: Japan Current & Future Analysis for CNS Therapeutics
by Segment - Pain Management, Anti-Psychotics,
Anti-Depressants, Anti-Epilepsy, Anti-Alzheimer`s,
Anti-Parkinson`s and Other Segments - Independent Analysis of
Annual Sales in US$ Million for the Years 2020 through 2027 and
% CAGR

Table 32: Japan Historic Review for CNS Therapeutics by Segment -
Pain Management, Anti-Psychotics, Anti-Depressants,
Anti-Epilepsy, Anti-Alzheimer`s, Anti-Parkinson`s and Other
Segments Markets - Independent Analysis of Annual Sales in US$
Million for Years 2012 through 2019 and % CAGR

Table 33: Japan 15-Year Perspective for CNS Therapeutics by
Segment - Percentage Breakdown of Value Sales for Pain
Management, Anti-Psychotics, Anti-Depressants, Anti-Epilepsy,
Anti-Alzheimer`s, Anti-Parkinson`s and Other Segments for the
Years 2012, 2020 & 2027

CHINA
China: The Primary Market for CNS Drugs in Asia-Pacific
Select Anti-Schizophrenia Drugs Available in China
Other Available CNS Drugs in China
Table 34: China Current & Future Analysis for CNS Therapeutics
by Segment - Pain Management, Anti-Psychotics,
Anti-Depressants, Anti-Epilepsy, Anti-Alzheimer`s,
Anti-Parkinson`s and Other Segments - Independent Analysis of
Annual Sales in US$ Million for the Years 2020 through 2027 and
% CAGR

Table 35: China Historic Review for CNS Therapeutics by Segment -
Pain Management, Anti-Psychotics, Anti-Depressants,
Anti-Epilepsy, Anti-Alzheimer`s, Anti-Parkinson`s and Other
Segments Markets - Independent Analysis of Annual Sales in US$
Million for Years 2012 through 2019 and % CAGR

Table 36: China 15-Year Perspective for CNS Therapeutics by
Segment - Percentage Breakdown of Value Sales for Pain
Management, Anti-Psychotics, Anti-Depressants, Anti-Epilepsy,
Anti-Alzheimer`s, Anti-Parkinson`s and Other Segments for the
Years 2012, 2020 & 2027

EUROPE
European Patent Expiries of Select CNS Drugs
Pain Management Market
Neuropathic Pain Market Witnesses Foray of Generics
Anti-Psychotics Market
Demand for Antipsychotics for Bipolar Disorder Upbeat
Ageing Population Boosts Demand
EXHIBIT 20: 65+ Population as Percentage of Total Population
for Major Countries in Europe: As on June 2019
Table 37: Europe Current & Future Analysis for CNS Therapeutics
by Geographic Region - France, Germany, Italy, UK, Spain,
Russia and Rest of Europe Markets - Independent Analysis of
Annual Sales in US$ Million for Years 2020 through 2027 and %
CAGR

Table 38: Europe Historic Review for CNS Therapeutics by
Geographic Region - France, Germany, Italy, UK, Spain, Russia
and Rest of Europe Markets - Independent Analysis of Annual
Sales in US$ Million for Years 2012 through 2019 and % CAGR

Table 39: Europe 15-Year Perspective for CNS Therapeutics by
Geographic Region - Percentage Breakdown of Value Sales for
France, Germany, Italy, UK, Spain, Russia and Rest of Europe
Markets for Years 2012, 2020 & 2027

Table 40: Europe Current & Future Analysis for CNS Therapeutics
by Segment - Pain Management, Anti-Psychotics,
Anti-Depressants, Anti-Epilepsy, Anti-Alzheimer`s,
Anti-Parkinson`s and Other Segments - Independent Analysis of
Annual Sales in US$ Million for the Years 2020 through 2027 and
% CAGR

Table 41: Europe Historic Review for CNS Therapeutics by
Segment - Pain Management, Anti-Psychotics, Anti-Depressants,
Anti-Epilepsy, Anti-Alzheimer`s, Anti-Parkinson`s and Other
Segments Markets - Independent Analysis of Annual Sales in US$
Million for Years 2012 through 2019 and % CAGR

Table 42: Europe 15-Year Perspective for CNS Therapeutics by
Segment - Percentage Breakdown of Value Sales for Pain
Management, Anti-Psychotics, Anti-Depressants, Anti-Epilepsy,
Anti-Alzheimer`s, Anti-Parkinson`s and Other Segments for the
Years 2012, 2020 & 2027

FRANCE
Table 43: France Current & Future Analysis for CNS Therapeutics
by Segment - Pain Management, Anti-Psychotics,
Anti-Depressants, Anti-Epilepsy, Anti-Alzheimer`s,
Anti-Parkinson`s and Other Segments - Independent Analysis of
Annual Sales in US$ Million for the Years 2020 through 2027 and
% CAGR

Table 44: France Historic Review for CNS Therapeutics by
Segment - Pain Management, Anti-Psychotics, Anti-Depressants,
Anti-Epilepsy, Anti-Alzheimer`s, Anti-Parkinson`s and Other
Segments Markets - Independent Analysis of Annual Sales in US$
Million for Years 2012 through 2019 and % CAGR

Table 45: France 15-Year Perspective for CNS Therapeutics by
Segment - Percentage Breakdown of Value Sales for Pain
Management, Anti-Psychotics, Anti-Depressants, Anti-Epilepsy,
Anti-Alzheimer`s, Anti-Parkinson`s and Other Segments for the
Years 2012, 2020 & 2027

GERMANY
Table 46: Germany Current & Future Analysis for CNS
Therapeutics by Segment - Pain Management, Anti-Psychotics,
Anti-Depressants, Anti-Epilepsy, Anti-Alzheimer`s,
Anti-Parkinson`s and Other Segments - Independent Analysis of
Annual Sales in US$ Million for the Years 2020 through 2027 and
% CAGR

Table 47: Germany Historic Review for CNS Therapeutics by
Segment - Pain Management, Anti-Psychotics, Anti-Depressants,
Anti-Epilepsy, Anti-Alzheimer`s, Anti-Parkinson`s and Other
Segments Markets - Independent Analysis of Annual Sales in US$
Million for Years 2012 through 2019 and % CAGR

Table 48: Germany 15-Year Perspective for CNS Therapeutics by
Segment - Percentage Breakdown of Value Sales for Pain
Management, Anti-Psychotics, Anti-Depressants, Anti-Epilepsy,
Anti-Alzheimer`s, Anti-Parkinson`s and Other Segments for the
Years 2012, 2020 & 2027

ITALY
Market Snapshots
Table 49: Italy Current & Future Analysis for CNS Therapeutics
by Segment - Pain Management, Anti-Psychotics,
Anti-Depressants, Anti-Epilepsy, Anti-Alzheimer`s,
Anti-Parkinson`s and Other Segments - Independent Analysis of
Annual Sales in US$ Million for the Years 2020 through 2027 and
% CAGR

Table 50: Italy Historic Review for CNS Therapeutics by Segment -
Pain Management, Anti-Psychotics, Anti-Depressants,
Anti-Epilepsy, Anti-Alzheimer`s, Anti-Parkinson`s and Other
Segments Markets - Independent Analysis of Annual Sales in US$
Million for Years 2012 through 2019 and % CAGR

Table 51: Italy 15-Year Perspective for CNS Therapeutics by
Segment - Percentage Breakdown of Value Sales for Pain
Management, Anti-Psychotics, Anti-Depressants, Anti-Epilepsy,
Anti-Alzheimer`s, Anti-Parkinson`s and Other Segments for the
Years 2012, 2020 & 2027

UNITED KINGDOM
NICE Recommendations on CNS Therapeutics
Table 52: UK Current & Future Analysis for CNS Therapeutics by
Segment - Pain Management, Anti-Psychotics, Anti-Depressants,
Anti-Epilepsy, Anti-Alzheimer`s, Anti-Parkinson`s and Other
Segments - Independent Analysis of Annual Sales in US$ Million
for the Years 2020 through 2027 and % CAGR

Table 53: UK Historic Review for CNS Therapeutics by Segment -
Pain Management, Anti-Psychotics, Anti-Depressants,
Anti-Epilepsy, Anti-Alzheimer`s, Anti-Parkinson`s and Other
Segments Markets - Independent Analysis of Annual Sales in US$
Million for Years 2012 through 2019 and % CAGR

Table 54: UK 15-Year Perspective for CNS Therapeutics by
Segment - Percentage Breakdown of Value Sales for Pain
Management, Anti-Psychotics, Anti-Depressants, Anti-Epilepsy,
Anti-Alzheimer`s, Anti-Parkinson`s and Other Segments for the
Years 2012, 2020 & 2027

SPAIN
Table 55: Spain Current & Future Analysis for CNS Therapeutics
by Segment - Pain Management, Anti-Psychotics,
Anti-Depressants, Anti-Epilepsy, Anti-Alzheimer`s,
Anti-Parkinson`s and Other Segments - Independent Analysis of
Annual Sales in US$ Million for the Years 2020 through 2027 and
% CAGR

Table 56: Spain Historic Review for CNS Therapeutics by Segment -
Pain Management, Anti-Psychotics, Anti-Depressants,
Anti-Epilepsy, Anti-Alzheimer`s, Anti-Parkinson`s and Other
Segments Markets - Independent Analysis of Annual Sales in US$
Million for Years 2012 through 2019 and % CAGR

Table 57: Spain 15-Year Perspective for CNS Therapeutics by
Segment - Percentage Breakdown of Value Sales for Pain
Management, Anti-Psychotics, Anti-Depressants, Anti-Epilepsy,
Anti-Alzheimer`s, Anti-Parkinson`s and Other Segments for the
Years 2012, 2020 & 2027

RUSSIA
Table 58: Russia Current & Future Analysis for CNS Therapeutics
by Segment - Pain Management, Anti-Psychotics,
Anti-Depressants, Anti-Epilepsy, Anti-Alzheimer`s,
Anti-Parkinson`s and Other Segments - Independent Analysis of
Annual Sales in US$ Million for the Years 2020 through 2027 and
% CAGR

Table 59: Russia Historic Review for CNS Therapeutics by
Segment - Pain Management, Anti-Psychotics, Anti-Depressants,
Anti-Epilepsy, Anti-Alzheimer`s, Anti-Parkinson`s and Other
Segments Markets - Independent Analysis of Annual Sales in US$
Million for Years 2012 through 2019 and % CAGR

Table 60: Russia 15-Year Perspective for CNS Therapeutics by
Segment - Percentage Breakdown of Value Sales for Pain
Management, Anti-Psychotics, Anti-Depressants, Anti-Epilepsy,
Anti-Alzheimer`s, Anti-Parkinson`s and Other Segments for the
Years 2012, 2020 & 2027

REST OF EUROPE
Table 61: Rest of Europe Current & Future Analysis for CNS
Therapeutics by Segment - Pain Management, Anti-Psychotics,
Anti-Depressants, Anti-Epilepsy, Anti-Alzheimer`s,
Anti-Parkinson`s and Other Segments - Independent Analysis of
Annual Sales in US$ Million for the Years 2020 through 2027 and
% CAGR

Table 62: Rest of Europe Historic Review for CNS Therapeutics
by Segment - Pain Management, Anti-Psychotics,
Anti-Depressants, Anti-Epilepsy, Anti-Alzheimer`s,
Anti-Parkinson`s and Other Segments Markets - Independent
Analysis of Annual Sales in US$ Million for Years 2012 through
2019 and % CAGR

Table 63: Rest of Europe 15-Year Perspective for CNS
Therapeutics by Segment - Percentage Breakdown of Value Sales
for Pain Management, Anti-Psychotics, Anti-Depressants,
Anti-Epilepsy, Anti-Alzheimer`s, Anti-Parkinson`s and Other
Segments for the Years 2012, 2020 & 2027

ASIA-PACIFIC
India & China Offer Significant Growth Opportunities
Growing Antipsychotics Market in Asia
Table 64: Asia-Pacific Current & Future Analysis for CNS
Therapeutics by Geographic Region - Australia, India, South
Korea and Rest of Asia-Pacific Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2020 through 2027 and
% CAGR

Table 65: Asia-Pacific Historic Review for CNS Therapeutics by
Geographic Region - Australia, India, South Korea and Rest of
Asia-Pacific Markets - Independent Analysis of Annual Sales in
US$ Million for Years 2012 through 2019 and % CAGR

Table 66: Asia-Pacific 15-Year Perspective for CNS Therapeutics
by Geographic Region - Percentage Breakdown of Value Sales for
Australia, India, South Korea and Rest of Asia-Pacific Markets
for Years 2012, 2020 & 2027

Table 67: Asia-Pacific Current & Future Analysis for CNS
Therapeutics by Segment - Pain Management, Anti-Psychotics,
Anti-Depressants, Anti-Epilepsy, Anti-Alzheimer`s,
Anti-Parkinson`s and Other Segments - Independent Analysis of
Annual Sales in US$ Million for the Years 2020 through 2027 and
% CAGR

Table 68: Asia-Pacific Historic Review for CNS Therapeutics by

Please contact our Customer Support Center to get the complete Table of Contents
Read the full report: https://www.reportlinker.com/p06050565/?utm_source=GNW

About Reportlinker
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

__________________________

CONTACT: Clare: clare@reportlinker.com US: (339)-368-6001 Intl: +1 339-368-6001